📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Glenmark Gets USFDA Approval for Fluticasone Propionate with 180-Day Exclusivity
Glenmark Specialty SA has received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol, a generic version of GSK's FloVent® HFA. The company has been granted 180-day Competitive Generic Therapy (CGT) exclusivity as the first approved applicant for this product. The target market for this therapy is valued at approximately $520.1 million annually as of January 2026. Commercial distribution in the U.S. is scheduled to begin immediately in March 2026, significantly strengthening Glenmark's respiratory portfolio.
Key Highlights
Received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol (44 mcg)
Granted 180-day Competitive Generic Therapy (CGT) exclusivity as the first approved applicant
Targets a market with annual sales of approximately $520.1 million according to IQVIA data
Commercial launch in the U.S. market is scheduled for March 2026
Product is bioequivalent and therapeutically equivalent to FloVent® HFA by GlaxoSmithKline
💼 Action for Investors
Investors should monitor the revenue contribution from this high-value launch during the 180-day exclusivity period, which is expected to improve U.S. margins. This approval validates Glenmark's technical capabilities in the complex respiratory segment.
Glenmark to Launch Sodium Phosphates Injection in US; Targets $66.8M Market
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Sodium Phosphates Injection USP in three single-dose vial presentations. The product is bioequivalent to Hospira's reference drug and is scheduled for distribution starting April 2026. According to IQVIA data, the market for this injection achieved annual sales of approximately $66.8 million for the 12-month period ending December 2025. This launch is part of Glenmark's strategy to expand its product portfolio within the US institutional channel.
Key Highlights
Launch of Sodium Phosphates Injection USP in 15 mM, 45 mM, and 150 mM single-dose vials.
Distribution in the US market is set to begin in April 2026.
Targets a market segment with annual sales of approximately $66.8 million as of December 2025.
Product is bioequivalent and therapeutically equivalent to Hospira, Inc.’s reference listed drug.
Strengthens Glenmark's presence in the US institutional channel and injectable portfolio.
💼 Action for Investors
Investors should monitor the successful rollout in April 2026 and the company's ability to capture market share from the $66.8 million pool. This launch supports Glenmark's long-term growth in the high-margin US injectables and institutional segments.
GST Department Conducts 5-Day Search Operation at Glenmark Pharmaceuticals Offices
The Goods & Service Tax (GST) Department, Mumbai, conducted a search and seizure operation at the offices of Glenmark Pharmaceuticals from January 27 to January 31, 2026. The inspection was carried out under Section 67 of the Maharashtra GST Act, 2017, and lasted for approximately five days. The company has stated that it fully cooperated with the officials and provided all requested documentation. Currently, no official document regarding adverse findings has been issued, and the company reports no material impact on its financials or operations.
Key Highlights
Search operation conducted by Assistant Commissioner of State Tax (Investigation – B), Mumbai
Inspection commenced on January 27, 2026, and concluded on January 31, 2026
Action initiated under Section 67 of the Maharashtra Goods and Services Tax Act, 2017
Company reports no material impact on financial or operational activities at this stage
No official adverse findings or tax demand notices have been issued following the conclusion of the search
💼 Action for Investors
Investors should monitor for any follow-up disclosures regarding tax demands or penalties resulting from this investigation. While the company claims no material impact, the five-day duration of the search warrants caution until a final clearance or demand notice is issued.
Glenmark Q3 FY26: Revenue Grows 15.1% to Rs 39,006 Mn; India Business Surges 22.1%
Glenmark Pharmaceuticals reported a strong Q3 FY26 with consolidated revenue rising 15.1% YoY to Rs 39,006 Mn, led by a robust 22.1% growth in the India business. The company maintained healthy profitability with an EBITDA margin of 22.3% and a PAT of Rs 4,032 Mn, despite an exceptional charge of Rs 1,843 Mn related to new labor codes. A significant regulatory milestone was achieved with the receipt of an EIR for the Monroe manufacturing site, clearing the path for restarted commercial production. The innovative portfolio continues to scale, with RYALTRIS gaining traction globally and WINLEVI receiving EU approval.
Key Highlights
Consolidated Revenue increased 15.1% YoY to Rs 39,006 Mn with an EBITDA of Rs 8,697 Mn.
India business grew 22.1% YoY, outperforming the market in Dermatology, Respiratory, and Cardiac segments.
North America core business grew 4.1% YoY; Monroe site received EIR with VAI status to restart manufacturing.
Innovative product RYALTRIS received approval in China, while WINLEVI was approved in the EU for a Q1 FY27 launch.
Reported PAT of Rs 4,032 Mn includes a one-time exceptional impact of Rs 1,843 Mn due to New Labour Codes.
💼 Action for Investors
Investors should take note of the strong domestic outperformance and the resolution of regulatory hurdles at the Monroe facility as key growth drivers. The steady transition toward an innovation-led portfolio provides a positive long-term outlook for margin sustainability.
Glenmark Q3 FY26: PAT Rises 15.9% to Rs 4,032 Mn; EBITDA Jumps 44.9% YoY
Glenmark Pharmaceuticals reported a strong Q3 FY26 performance with consolidated revenue growing 15.1% YoY to Rs 39,006 Mn. The company achieved a significant 44.9% YoY growth in EBITDA, reaching Rs 8,697 Mn with a healthy margin of 22.3%. Growth was robust across key markets, particularly in India (up 22.1%) and North America (up 24.2%), though the latter included out-licensing income. A major operational milestone was achieved with the US FDA granting VAI status to the Monroe facility, allowing for the restart of commercial manufacturing.
Key Highlights
Consolidated revenue increased 15.1% YoY to Rs 39,006 Mn for Q3 FY26.
EBITDA surged 44.9% YoY to Rs 8,697 Mn with margins expanding to 22.3% from the previous year.
India Formulations business grew 22.1% YoY to Rs 12,986 Mn, outperforming the general market growth.
Received US FDA Establishment Inspection Report (EIR) with VAI status for the Monroe, North Carolina facility.
North America revenue grew 24.2% YoY to Rs 9,706 Mn, aided by out-licensing income for ISB 2001.
💼 Action for Investors
Investors should take note of the significant margin expansion and the resolution of regulatory hurdles at the Monroe plant, which clears a path for future US launches. The company's strong domestic performance and scaling of innovative brands like Ryaltris make it a solid hold with a positive outlook.
Glenmark Q3 FY26 Net Profit Rises 15.8% YoY to ₹4,032 Million; Revenue Up 15%
Glenmark Pharmaceuticals reported a consolidated revenue of ₹39,006 million for Q3 FY26, marking a 15.1% increase compared to ₹33,875 million in the same quarter last year. Net profit for the quarter grew by 15.8% YoY to ₹4,032 million, even after accounting for an exceptional loss of ₹1,843 million. These exceptional items primarily relate to a US antitrust settlement with United Healthcare for $11 million and adjustments for new labor codes in India. For the nine-month period, the company showed robust growth with revenue reaching ₹1,32,119 million, up 31.2% YoY.
Key Highlights
Consolidated revenue from operations grew 15.1% YoY to ₹39,006.15 million in Q3 FY26.
Net profit (PAT) increased to ₹4,032.28 million from ₹3,480.31 million in the previous year's quarter.
Exceptional items for the quarter totaled ₹1,843.37 million, including a $11 million US antitrust settlement.
Basic EPS for the quarter stood at ₹14.29, up from ₹12.33 in Q3 FY25.
Nine-month consolidated revenue reached ₹1,32,119.25 million, a significant jump from ₹1,00,655.33 million YoY.
💼 Action for Investors
Investors should focus on the strong double-digit operational growth and the company's ability to maintain profitability despite legacy legal settlements. The stock remains a watch for further margin improvements as one-time legal costs subside.
Glenmark Launches Epinephrine Injection in USA Targeting $67.6 Million Market
Glenmark Pharmaceuticals Inc., USA has launched Epinephrine Injection USP (30 mg/30 mL) Multiple-Dose Vial in the United States. This product is bioequivalent and therapeutically equivalent to the reference drug from BPI Labs, LLC. The launch targets a market with annual sales of approximately $67.6 million as of October 2025. This move is intended to strengthen Glenmark's institutional channel portfolio and its presence in the North American generics market.
Key Highlights
Launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial in the US market.
Targets an addressable market size of approximately $67.6 million in annual sales.
Product is therapeutically equivalent to BPI Labs, LLC’s reference listed drug (NDA 205029).
Aims to expand the company's footprint within the US institutional channel for injectable products.
💼 Action for Investors
Investors should view this as a positive step in Glenmark's US generic strategy, contributing to steady revenue growth. Monitor the company's market share gains in the injectables segment over the coming quarters.
Glenmark Secures Exclusive Rights for Lung Cancer Drug Aumolertinib in $1 Billion Deal
Glenmark's subsidiary, GSSA, has entered into an exclusive licensing agreement with Hansoh Pharma for Aumolertinib, a third-generation lung cancer treatment. The deal grants Glenmark rights across the Middle East, Africa, Southeast Asia, Australia, and Russia/CIS. Glenmark will pay a low double-digit million USD upfront, with potential milestone payments exceeding $1 billion plus tiered royalties. This strategic move significantly bolsters Glenmark's oncology portfolio with a drug already approved by the UK MHRA and China's NMPA.
Key Highlights
Exclusive rights for Aumolertinib in Middle East, Africa, SE Asia, Australia, and Russia/CIS.
Upfront payment of low double-digit million USD to Hansoh Pharma.
Potential regulatory and commercial milestones totaling over US$1 billion.
Aumolertinib is a third-generation EGFR-TKI approved for various non-small cell lung cancer indications.
The drug is already marketed as Ameile in China and Aumseqa in the United Kingdom.
💼 Action for Investors
Investors should view this as a strong strategic expansion into the high-growth oncology segment. Monitor the commercial rollout and regulatory approvals in the newly licensed territories for long-term revenue impact.
Glenmark to Launch Leucovorin Calcium Injection in US; Targets $16.8 Million Market
Glenmark Pharmaceuticals Inc., USA is set to launch Leucovorin Calcium for Injection USP (350 mg/vial) in the United States in December 2025. The product is a bioequivalent and therapeutically equivalent version of Hospira's reference drug. According to IQVIA data, the annual market for this specific injection was approximately $16.8 million for the 12-month period ending October 2025. This launch aligns with Glenmark's strategy to expand its institutional channel portfolio and provide affordable alternatives in the North American market.
Key Highlights
Launch of Leucovorin Calcium for Injection USP, 350 mg/vial in the US market starting December 2025.
Targets an annual market size of approximately $16.8 million based on IQVIA sales data.
Product is bioequivalent to the reference listed drug (RLD) from Hospira, Inc.
Expansion of the company's institutional channel portfolio in North America.
Strengthens Glenmark's presence in the oncology-supportive care segment.
💼 Action for Investors
Investors should monitor the ramp-up of Glenmark's US generic portfolio, as consistent small-to-mid-sized launches contribute to steady revenue growth in the North American segment. No immediate action is required as the market size is relatively modest compared to the company's total revenue.
Glenmark's Aurangabad Facility Receives Zero Observations from US FDA Inspection
Glenmark Pharmaceuticals has successfully completed a US FDA Pre-Approval Inspection (PAI) at its formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad). The inspection was conducted from November 24 to November 28, 2025, and concluded with zero Form 483 observations. This clean audit report is a significant positive for the company, as it indicates full compliance with US regulatory standards. It clears a major hurdle for the approval and launch of new products from this facility into the US market.
Key Highlights
US FDA completed a Pre-Approval Inspection (PAI) at the Aurangabad formulations facility.
The inspection took place over five days from November 24 to November 28, 2025.
The audit concluded with zero Form 483 observations, the best possible regulatory outcome.
Successful inspection paves the way for future product approvals and exports to the US market.
💼 Action for Investors
Investors should view this as a strong positive development that reduces regulatory risk and supports future growth in the US market. No immediate action is required other than maintaining a positive outlook on the stock's compliance profile.